leisure time -WSS

leisure time

author：leisure time 2025-09-06 06:20:09 Page View：79

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Does good food count as health care? Study aims to find out
Next article： Activists slam private health insurers over coverage restrictions

explore

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Medical device trials still don't enroll enough women, study finds

AdobeWomenhavealwaysbeenunderrepresentedinmedicalresearch.Anewstudyrevealsthatnotmuchhaschanged,espe

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Anthos stroke drug appears safer than common blood thinner

AdobePHILADELPHIA—Aninvestigationaldrugaimedatpreventingstrokessignificantlyreducedtheriskofbleeding

leisure time

knowledge

explore

Anthos stroke drug appears safer than common blood thinner